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Abstract
Perfluorooctanoic acid (PFOA) is a known developmental toxicant in mice, with varied strain 
outcomes depending on dose and period of exposure. The impact of PFOA on female mouse 
pubertal development at low doses (≤1 mg/kg), however, has yet to be determined. Therefore, 
female offspring from CD-1 and C57Bl/6 dams exposed to PFOA, creating serum concentrations 
similar to humans, were examined for pubertal onset, including mammary gland development. 
Mouse pups demonstrated a shorter PFOA elimination half-life than that reported for adult mice. 
Prenatal exposure to PFOA caused significant mammary developmental delays in exposed female 
offspring in both strains. Delays started during puberty and persisted into young adulthood; 
severity was dose-dependent. In contrast, an evaluation of serum hormone levels and pubertal 
timing onset in the same offspring revealed no effects of PFOA compared to controls in either 
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strain. Therefore, our data suggest that the mammary gland is more sensitive to the effects of early 
low level PFOA exposures compared to other pubertal endpoints, regardless of strain.
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1. Introduction
Perfluorooctanoic acid (PFOA) is an eight carbon member of the perfluoroalkyl acid family. 
Its use as a surfactant in various industrial and consumer products, as well as its ability to 
resist further degradation under extreme temperatures, has made it both persistent and 
ubiquitous within the environment resulting in the inevitable exposure to both humans and 
wildlife.
Serum PFOA levels in the general U.S. population have declined from 5.21 ng/mL 
(1999-2000) to 3.07 ng/mL over a decade (2009-2010) [1], potentially due to consumer 
awareness and a gradual phase out of PFOA production in the U.S. However, residents 
living in areas of elevated PFOA exposure (sites near manufacturing facilities) have serum 
levels 10-100 times higher than the national average, and children aged 2-5 years 
demonstrated a geometric mean serum concentration of 600 ng/ml (as of 2006) [2]. Pubertal 
aged children from this area also experienced higher total geometric mean serum levels (<12 
years, 77.6 ng/ml and 12-19 years, 59.9 ng/ml) [3]. Exposure at these ages is mostly related 
to drinking water sources but may also be contributed to by the ingestion of contaminated 
dust, food sources and hand to mouth contact. PFOA exposure may also occur during 
gestation or shortly after birth, as PFOA was detected in human and rodent milk, rodent 
serum, urine, amniotic fluid and at relatively low levels in human cord blood [4, 5 and 6]. 
These findings suggest that PFOA is not only capable of being transferred from mother to 
offspring due to its long half-life (3.8-4.4 years in humans [7]), but that the longer the 
exposure, the higher the potential is for increased serum PFOA levels in offspring. Parental 
exposures prior to conception may compromise embryonic development and continued 
placental and lactational [8] exposures may have deleterious effects on the developing fetus, 
newborn and infant. Early life exposures to PFOA may induce alterations in the epigenome, 
such as altered DNA methylation [9, 10], that have the potential to alter normal development 
and lead to adverse health outcomes in later life.
High dose exposures in adult rodents (≥10 mg/kg PFOA) have resulted in hepatotoxicity, 
tumors of the liver and pancreas and in pregnant adult mice, neonatal toxicity and mortality 
of their offspring [11, 12 and 13]. Lower perinatal doses, however, have resulted in an array 
of reproductive and developmental alterations in mouse offspring that have included 
advanced preputial separation in males, sex specific neurobehavioral differences [14] and 
impaired mammary gland development [15]. The mammary gland is a unique organ in that 
the majority of its development occurs postnatally. Although differentiation is not complete 
until late pregnancy, puberty demarks an exponential growth phase that is facilitated by 
various paracrine and endocrine factors including estrogen and progesterone and includes an 
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increased mammary stem cell population [16, 17, and 18]. Additionally, the highly 
proliferative terminal end buds (TEBs) lead the migration of the mammary epithelium into 
the fat pad resulting in the extensive ductal branching patterns of the gland. Exposures to 
endocrine disrupting chemicals (EDCs) during gestation or early life are especially of 
concern because they may affect the normal progression of mammary development that may 
not become apparent until puberty or later life. EDCs can disrupt normal functions by 
mimicking naturally occurring hormones, inhibiting hormone receptor binding or causing an 
abnormal inhibitory or stimulatory endocrine response [19]. High dose PFOA exposure has 
demonstrated these properties in the mammary gland by stimulating growth in the glands of 
peripubertal exposed C57Bl/6 female mice [20]. These effects were only apparent when the 
ovaries were present and also resulted in the upregulation of estrogen receptor alpha (ERα) 
expression within the gland. However, the mechanism for prenatal PFOA exposure on 
mammary gland development has yet to be determined, but it is evident that early exposures 
set in motion key alterations that may be exacerbated by circulating endogenous hormones. 
This could potentially further target the proliferating TEBs resulting in the increased 
potential for cellular transformations that may make the gland more susceptible to 
developing later life diseases, such as breast cancer [21, 22].
Full and late gestational exposure to low dose PFOA has been shown to induce stunted 
mammary epithelial growth in CD-1 female offspring, an abnormality that persisted into 
adulthood, which can begin as early as postnatal day (PND) 56 in some mouse strains. 
Macon et al. [15] reported adverse changes in female CD-1 mouse mammary gland 
development from 0.01 to 1 mg/kg PFOA following a late gestation exposure, which is 
defined as a one-time daily oral gavage exposure between gestational days 10-17. 
Multigenerational effects have also been observed in CD-1 mice administered separate and 
combined oral gavage and drinking water exposure to 5 μg/L PFOA. All PFOA treated F1 
females demonstrated reduced mammary development that continued until 63 days of age 
(young adulthood) [23]. Mammary development was also attenuated at weaning in F2 
females that were never exposed to PFOA via placental transfer. Much higher oral 
exposures appear to be required for mammary effects in other strains, using peripubertal 
exposures. Yang et al. [24] reported striking differences among C57Bl/6 and Balb/c mice 
peripubertally exposed to ≥5 mg/kg PFOA. Peripubertal PFOA exposure significantly 
inhibited mammary growth at 5 and 10 mg/kg in Balb/c animals, whereas in C57Bl/6 mice 
stimulatory effects were reported at 5 mg/kg, but inhibitory effects predominated at 10 
mg/kg. Mammary gland development was not altered in either strain following peripubertal 
exposures at 1.0 mg/kg suggesting that some mouse strains are more sensitive than others to 
PFOA effects and/or the effects in the mammary gland are highly dependent upon the timing 
of exposure (peripubertal vs. in utero).
PFOA has also been associated with changes in other pubertal developmental landmarks. 
Girls living in close proximity to PFOA-polluted areas have self-reported delays in 
menarche that were associated with increased serum PFOA levels [25]. Rodent models have 
also been assessed for similar hallmarks that include timing of first estrus, vaginal opening 
(VO) and estrous cyclity, as the onset of cyclity occurs after VO and first estrus; VO and 
first estrus in prenatally exposed pups were slightly delayed at dose levels outside those that 
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humans would be exposed to (20 mg/kg) and unchanged at the lowest dose tested (1.0 
mg/kg) [13]. EDCs have been reported to elicit non-monotonic responses, wherein lower 
doses may produce changes not observed at higher doses [26]. To date, no study has 
examined the low-dose effects of PFOA on all pubertal events in prenatally exposed female 
mice nor determined how the mouse strain may influence any potential effects. Our goal was 
to provide a thorough evaluation of the low dose effects of PFOA exposure on the timing of 
critical pubertal events in the CD-1 and C57Bl/6 female mouse including mammary gland 
development, VO and first estrus, in addition to the evaluation of serum steroid hormone 
and PFOA levels. These assessments may provide valuable information as to the most 
sensitive pubertal targets influenced by prenatal PFOA exposure, as well as indicate 
pathways that may be perturbed by other related toxicants during pubertal onset.
2. Materials and Methods
2.1 PFOA
Perfluorooctanoic acid (PFOA, ammonium salt; >98% pure) was obtained from Fluka 
Chemical (Steinheim, Switzerland) and 1, 2-13C2-perfluoroctanoic acid (13C2-PFOA) was 
purchased from PerkinElmer Life and Analytical Sciences (Boston, MA). PFOA dosing 
solutions were dissolved in deionized water (DI water) and freshly prepared daily.
2.2 Animals
Timed pregnant CD-1 and C57Bl/6 mice were obtained from Charles River Laboratories 
(Raleigh, NC) on gestational day 0 (GD 0) when they were confirmed sperm positive. Upon 
arrival, each dam was weighed and randomly assigned to one of five treatment groups, 
equalizing the mean starting body weight in each group. Pregnant dams were individually 
housed in polypropylene cages with microbarrier lids and received chow (LabDiet 5001, 
PMI Nutrition International LLC, Brentwood, MO) and tap water ad libitum. Animal 
facilities were maintained on 12:12h light-dark cycle, at a controlled temperature (20-24 
°C), with 40-60% relative humidity. All animals were treated humanely and in accordance 
with the National Institute of Environmental Health Sciences Animal Care and Use 
Committee (ACUC).
2.3 Experimental Design
For space reasons, the studies in CD-1 mice were completed in three blocks (block 1 n=97, 
block 2 n= 40, and block 3 n=26). Studies with the C57Bl/6 animals were completed in one 
block (n=41). For each experimental block, timed pregnant dams were orally gavaged daily 
with vehicle (DI water), 0.01, 0.1, 0.3 or 1.0 mg PFOA/kg/body weight (bw) between GD 
1-17. A full gestation exposure design was chosen to recapitulate murine serum levels that 
have been established in previous experiments and were found to overlap with PFOA serum 
levels in residents living in heavily contaminated areas in the U.S. Dams were weighed daily 
to administer a dose volume of 10 μl/g bw. Parturition normally occurred on the eve of GD 
18 and PND 1 was defined as the first day following parturition (usually > 0.5 days old). On 
PND 3, pup sex was determined and CD-1 litters were equalized to 10 pups per dam. If 
numbers permitted, each dam received 6-7 females and 3-4 males. Pregnancy rates in CD-1 
females were >60% (block 1 =78% block 2 =67% and block 3 = 88%); however, the 
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C57Bl/6 block yielded a much lower rate of approximately 27% (41/152). Regardless of 
treatment, C57Bl/6 dams produced litter sizes of between 5-8 pups. Any litters with an n<5 
pups were excluded from these studies. On PND 21, pups of both strains were weaned and 
all female pups were retained and housed 3-5 mice per cage in an effort to keep litter mates 
together. Male weanlings from controls were retained in order to circulate pheromones into 
the room that are known to assist in normalizing female cycling [27, 28]. Additionally, every 
3-4 days (at cage changes) a small sample of bedding from the males was placed into each 
female cage.
2.4 Necropsy
With the exception of PND 21 (sexually immature), vaginal lavage was performed on all 
females prior to necropsy to determine their stage of the estrous cycle. We attempted to 
necropsy females during the first day of estrus in order to minimize morphological and 
hormonal fluctuations caused by normal changes in the estrous cycle. Vaginal smears were 
acquired between 6 and 8 AM on the day of sacrifice and necropsied shortly thereafter (9 
AM-12 PM) [29]. On PND 21, 35, and 56 for CD-1 mice (n=4-7 litters/treatment), and PND 
21(n=2-6 litters/treatment) and 61 (n= 3-9litters/treatment) for C57Bl/6 mice (fewer time 
points due to this strain historically having fewer pups per live birth and low pregnancy rates 
following plug identification) female pups were first weighed and then sacrificed using swift 
decapitation to obtain trunk blood for PFOA and hormone analysis. Mammary glands were 
collected from the fourth and fifth inguinal glands and prepared as carmine stained whole 
mounts. Body and liver weights were also recorded.
2.5 Pubertal Endpoints
Pubertal maturation in females was assessed using VO and vaginal cytology to determine 
timing to first estrus in the estrous cycle. Visual assessment for VO started on PND 18 in 
CD-1 mice and on PND 23 in C57Bl/6 mice, as VO has been reported to begin as late as 
PND 30 in that strain [30]. Once VO occurred, daily vaginal lavage was performed using 1X 
phosphate buffered saline and a sterile eyedropper to obtain cells to determine the presence 
of cornified epithelial cells, the first indication of estrus [13, 31]. All samples were evaluated 
fresh daily on a Leica DM2000 light-microscope (Leica Microsystems). Body weights were 
taken daily and recorded on the day of VO and first estrus. Pubertal endpoints were only 
measured in CD-1 block 1 (n= 7-8/treatment) and 2 (n=4-5/treatment) litters. Three to seven 
C57Bl/6 pups were evaluated per litter.
2.6 Mammary Whole Mount Preparation and Analysis
The entire fourth and fifth mammary gland from each mouse was placed on a charged slide 
and flattened to the natural surface area. Each whole mount was fixed in Carnoy’s solution 
(EtOH, acetic acid and chloroform), stained in carmine alum and de-fatted in xylene [32]. 
For each collection, all samples were compared to age-matched animals within the same 
group and across other treatment groups [32]. Each gland was assessed and assigned a 
qualitative score on a scale of 1-4 (1=poor development and 4=best development) using a 
Leica Z16APO and DFC295 light microscope and camera (Leica Microsystems Inc., 
Buffalo Grove, IL), respectively. Qualitative scoring criteria is based on, but not limited to, 
lateral and longitudinal epithelial growth, branching density, changes in epithelial growth, 
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appearance of budding from ductal tree, number of differentiating duct ends and the 
presence or absence of terminal end buds. Each gland was scored by two individuals without 
knowledge of treatment and averaged to obtain a final score [15]. Approximately, 4-7 CD-1 
females/treatment/block and 2-10 C57Bl/6 offspring/treatment were scored.
2.7 PFOA Serum
Serum concentrations of PFOA were obtained using the methods reported by Reiner et al. 
[33]. Briefly, 25-50 μL of serum from each individual was transferred to its own 15 ml 
propylene tube. A predetermined amount of internal standard (13C2-PFOA) was added to 
approximate the midpoint of the calibration curve for the anticipated sample range. 0.1 M 
Formic acid was added to the sample to denature the proteins and it was vortexed. Cold 
acetonitrile (-20C) was added to precipitate the proteins followed by vortexing and 
centrifugation at 2000 x g for 3 min. Supernatant from the acetonitrile mixture were placed 
in liquid chromatography vials containing ammonium acetate buffer (pH 6.5) (1:1). All 
samples were analyzed using a Waters Acquity Ultra Performance Liquid Chromatograph 
interfaced with a Waters Quattro Premier XE triple quadropole mass spectrometer (Waters 
Corporation, Milford, MA). Blank matrices were obtained using Pel-Freeze Biologicals 
CD-1 control mouse serum (Rogers, AR). At least six standards were used to generate the 
calibration curve with the coefficients of determination at 0.99 or higher. Calibration curves 
were obtained by plotting the ratio of PFOA peak area to 13C2-PFOA peak area vs. 
concentration and were fitted to a linear regression equation with 1/x weighting. The limit of 
quantitation (LOQ) was defined as the lowest point on the standard curve at which analysis 
may be reported +/− 30% confidence. Quality control (QC) samples were interspersed 
throughout the analytical run and were run in duplicates for accuracy determination. Method 
accuracy and precision were determined by analyzing the QC samples repeatedly. Accuracy 
was calculated as the percentage of the concentration found compared with the theoretical 
concentration and the precision was calculated using the average relative standard deviation 
of the replicate analysis of the QC materials. Additionally, approximately 10% of all 
unknown samples were analyzed in duplicate for precision measurements. Each sample 
batch run contained a calibration standard and a matrix and methanol blank that were 
prepared under the same conditions as the unknown samples. The LOQ for CD-1 serum 
samples ranged from 5-100 ng/ml (Control=5 ng/ml, 0.01mg/kg=10 ng/ml, 0.1, 0.3 and 1.0 
mg/kg=100 ng/ml). The LOQ for C57Bl/6 animals was 10 ng/ml. Samples that were below 
the LOQ were reported as the LOQ /√2 for statistical purposes. Serum PFOA was measured 
from at least one pup from each litter per treatment group in the CD-1 (n=5-10) and C57Bl/6 
(n= 2-6) studies.
2.8 Serum Estradiol and Progesterone Analysis
Serum estradiol and progesterone levels were measured using a commercially available 
assay kit (Meso Scale Discovery, Gaithersburg, MD). Coefficients of variation ≤ 20% were 
considered acceptable. Assays were performed in a multiplex format in 96-well, 4 spot 
plates that were pre-coated with estradiol and progesterone capture antibodies and 50 μl 
serum samples. Sandwich immunoassays were conducted by adding test serum followed by 
conjugated detection antibodies (anti-estradiol and anti-progesterone) containing an 
electrochemiluminescent compound. Electrochemiluminescence was detected using a 
Tucker et al. Page 6













SECTOR Imager 2400. Quantitation of estradiol or progesterone was based on the intensity 
of the emitted light. A rat serum sample of known concentration was also tested for QC 
purposes. Data from the Sector Imager was transferred to Excel worksheets for further 
analysis. The limit of detection (LOD) for estradiol was 5 pg/ml and 0.07 ng/ml for 
progesterone.
All unknown serum samples were analyzed in duplicate and standard curves for estradiol 
and progesterone were generated using calibrators supplied with the kit. Estradiol 
concentrations between 0 and 4 ng/ml and progesterone concentrations between 0 and 50 
ng/ml were fitted to a sigmoid dose response curve and used to quantify the level of each 
hormone in test samples. Serum samples from each treatment group were stratified across 
plates so that not all of one dose group was assayed on the same plate.
2.9 Statistical Analysis
For all studies, dams or litters were considered the unit of measurement. Therefore, if a dam 
was represented by more than one pup, their values were averaged. Outlier values were 
determined by bodyweight and were calculated using GraphPad’s QuickCalc Grubb’s test 
(http://graphpad.com/quickcalcs/grubbs1/). Outliers were only removed when the animal 
presented as being moribund. When an individual animal was found to be an outlier within a 
specific end point, the data for that individual was removed from all data sets that it was 
contained in. Replicated experiments were treated as blocks and were analyzed using two-
way analysis of variance (ANOVA) to determine block and treatment effects using Tukey’s 
post hoc test (p<0.05). A linear regression test was performed on the mammary gland scores 
to determine dose related effects. Serum PFOA, estradiol and progesterone levels were 
assessed using ANOVA followed by a Dunnett’s post hoc test. Graphs and tables were 
created using GraphPad Prism 6 (La Jolla, CA) and Microsoft Excel. All data are 
represented as the mean ± SEM.
3. Results
3.1 Internal PFOA burdens and liver enlargement
Serum PFOA concentrations in exposed female offspring were measured to determine the 
internal concentrations at which pubertal effects were being observed. PFOA levels were 
detectable in all exposed female offspring from both strains at PND 21 (Table 1). PFOA was 
undetectable in control mice of both strains. Serum PFOA concentrations increased in a dose 
dependent manner and were significantly different at the two highest doses in the CD-1 
females at PND 21 and 35 compared with control females. Detectable levels were measured 
in all treated animals at PND 35, however, by PND 56 all animals experienced a 4-5 fold 
decrease in serum levels compared to littermates collected at PND 35, a decrease that was 
larger than expected, given the reported 15.6-21.7 d half-life of PFOA in adult CD-1 mice 
[34] following a single oral adulthood exposure [34]. By PND 56, serum PFOA levels were 
below LOQ in the 0.01mg/kg group and only statistically increased from control levels at 
1.0 mg/kg. The same dose dependent trend observed at PND 21 in CD-1 mice was also 
shown in the C57Bl/6 pups; however, differences were not significant, more than likely 
reflecting the fair amount of variability between mice in a small litter size, rather than 
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treatment. Additionally, treatment with the same PFOA exposures in C57Bl/6 mice resulted 
in serum levels that were lower on average compared to those observed in the CD-1 strain of 
the same age. By PND 61 the C57Bl/6 animals in the three highest dose groups had 
measurable levels that were still above the LOQ threshold, however, these levels were 
~10-100 fold reduced from those observed in their PND 21 litter mates. Taken together, 
these data suggest a faster rate of clearance of PFOA from the C57Bl/6 offspring and 
potentially a faster clearance in rapidly growing offspring than the 15.6-21.7 d half-life 
previously reported in adult CD-1 mice [34]. Based on our 1.0 mg PFOA/kg data and serum 
data collected previously [15], we estimated half-life clearance in the CD-1 animals between 
PND 21 to PND 56 to be 7.3-8.9 days and C57Bl/6 to be 6.0 days between PND 21 and 
PND 61.
Full gestation PFOA exposure (0.01 to 1 mg/kg) did not affect absolute body weight 
measurements in either CD-1 or C57Bl/6 female offspring (Tables 2 and 3, respectively). 
Net body weight was defined as the liver weight subtracted from the body weight and was 
found to be significantly reduced in the highest dose group in CD-1 females (1.0 mg/kg) at 
PND 21 and 35. This effect had little biological significance, as it resolved and net body 
weights were comparable to the control levels by PND 56. These finding are in agreement 
with the body weights observed at post weaning ages following a full gestation exposure to 
PFOA levels ≤ 1.0 mg/kg [13, 15]. No significant effects for net body weight were observed 
in the C57Bl/6 females.
Absolute liver weight differences in both strains were not significantly altered in comparison 
to their respective controls (Tables 2 and 3). CD-1 females in the 1.0 mg/kg dose group 
exhibited significantly elevated relative liver weights at PND 21 that recovered to normal 
levels by PND 35. As relative liver weights had returned to values similar to controls by 
PND 28 following a full gestational exposure in a previous study, our transient finding is 
thought to be biologically irrelevant [15]. C57Bl/6 mice did not demonstrate any significant 
relative liver weight changes at PND 21 or PND 61. Together these data confirm that liver 
effects resulting from early and low exposures are transient and may begin to dissipate 
during early puberty. This appears to correlate well with the higher internal body burdens in 
CD-1 mice that showed increased liver hypertrophy (relative liver weight) in 1 mg PFOA/kg 
bw weanlings compared to no effects seen in C57Bl/6 pups (Tables 2 and 3).
3.2 Pubertal Assessment
Pubertal onset in the female mouse is associated with an increased production of the steroid 
hormones estradiol and progesterone as a result of increased signaling from the 
hypothalamus and pituitary gland to the ovaries. Both hormones are critical for ovulation 
and uterine changes, as well as normal mammary gland development and sexual maturation 
[35, 36]. To understand the effects of prenatal PFOA on circulating steroids, serum was 
obtained from females in the stage of estrus, except at PND 21 where all hormone analysis 
samples were from females that had not undergone VO. Figure 1A illustrates that estradiol 
levels in both strains were similar between PFOA treated and control mice. A similar lack of 
statistical difference for treatment effect was shown for progesterone (Figure 1B), however; 
progesterone levels were overall elevated in CD-1 animals at PND 56, in all exposure 
Tucker et al. Page 8













groups, compared to levels seen at PND 21 and 35. Progesterone levels in PFOA-exposed 
C57Bl/6 females were comparable to control at both PND 21 and 61.
An assessment of the effects of PFOA on VO and first estrus are summarized in Table 4. 
Females from only two of the three CD-1 blocks were measured. Although all assessments 
were completed in an identical manner, it was necessary to assess each block separately due 
to block effect differences. VO occurred ~4 days later in block 2 compared to block 1, 
however, comparisons between the control and treatment groups within each block revealed 
no significant differences due to treatment. The reason for the block difference could not be 
determined. Timing to first estrus was also unchanged within each block. However, block 1 
females appeared to undergo their average first estrus 2-3 days following VO whereas it 
almost immediately followed VO in block 2 females, with the exception of the 1.0 mg/kg 
group (~2.5 days timing to first estrus). Neither body weight at VO nor first estrus timing 
was changed by PFOA treatment in either block. The age of VO, day of first estrus and body 
weights at these times was also unchanged in the C57Bl/6 animals. The fact that no 
treatment related effects were observed in either strain implies that the differences in the 
normal timing of these events in each strain are likely a result of strain differences rather 
than PFOA exposure.
The effects of PFOA on mammary gland development were assessed by whole mount using 
factors that include lateral and longitudinal branching, the presence or absence of terminal 
end buds and branching density. However, these criteria were dependent upon the age of 
development. Both CD-1 and C57Bl/6 strains exhibited developmental delays that were 
apparent at the lowest dose (0.01 mg/kg) and were significantly different from controls in 
CD-1 mice. As early as PND 21 we observed a dose dependent decrease in developmental 
scores in the CD-1 animals with the highest dose group scoring ~1.2 points lower than 
control (Table 5). Score reductions were significant at PND 21 in the three highest dose 
groups (0.1-1.0 mg/kg); however, by PND 35 and 56 growth delays were obvious in all 
CD-1 treatment groups resulting in significantly lower scores. When a trend analysis was 
performed on the mammary developmental scores of CD-1 mice, an inverse relationship was 
noted between scores and PFOA dose (p<0.001), indicating that increased dose induced the 
developmental delays observed. Representative morphological evaluations of the CD-1 
glands are illustrated in Figure 2. TEBs, lateral and longitudinal branching and secondary 
branching were all decreased with increased PFOA dose, resulting in a much smaller gland 
(Figure 2). By PND 35, in addition to the growth defects already described, PFOA caused a 
delay in the fourth and fifth glands growing together. Although, our evaluation of pubertal 
timing in both strains has established that C57Bl/6 animals reach sexual maturation at a later 
point than CD-1 mice, mammary glands were still evaluated on PND 21 to remain consistent 
throughout each block. We did note that control scores from both strains were very similar; 
it should be noted that scoring is based on the level of development compared to controls 
and may be based on entirely different criteria that can still result in similar scores across 
strains.
In the C57Bl/6 strain, only the 0.3 and 1.0 mg PFOA/kg offspring demonstrated mammary 
developmental scores that were significantly reduced from that of controls (Table 5). A 
trend analysis confirmed a similar trend as those seen in the CD-1 mice, in which higher 
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PFOA doses induced mammary developmental delays. The presence of TEBs was minimal 
at PND 21, considering that estradiol levels in both strains at this time point were within the 
same range. However, significant defects in branching density due to PFOA exposure were 
visible in the 0.3 and 1.0 mg/kg PFOA groups at both PND 21 and 61 (Table 5). C57Bl/6 
PFOA treated animals exhibited, at most, minimal budding and secondary branching with 
little to no lateral and longitudinal branching (Figure 3). At PND 61, the C57Bl/6 glands at 
the highest dose still had TEBs and internal budding throughout the fat pad; whereas at the 
same time point control glands were almost fully matured. This demonstrates that there are 
significant differences in the natural rate of mammary gland development in two different 
strains. Also, the impact of PFOA treatment on C57Bl/6 females was not as severe as that 
seen in CD-1 females and is likely due to differences in body burden, as serum PFOA levels 
were lower in C57Bl/6 than CD-1 across dose groups at the same ages. Regardless of those 
strain differences, the effects of PFOA on mammary gland development persisted in both 
strains through early adulthood.
4. Discussion
The objective of these studies was to determine the pubertal development effects of early 
life PFOA exposures, which produce serum concentrations in the CD-1 and C57Bl/6 female 
mice that coincide with reported human blood PFOA concentrations in contaminated areas, 
specifically evaluating for dose and strain-related effects. Perinatal low dose exposures to 
PFOA resulted in greater alterations in the pubertal mammary gland for both strains 
compared to all other measured pubertal endpoints. Mammary gland developmental delays 
were visible as early as PND 21 in both strains and were significantly different from controls 
at concentrations as low as 0.01 mg/kg in the CD-1 mouse. Our study suggests that at these 
low doses the strain differences, in response to PFOA, are dose dependent. Given identical 
oral doses during the exact same window of exposure, both strains experienced delayed 
mammary development at 0.3 and 1.0 mg/kg PFOA and lacked changes in the timing of 
other pubertal events. The CD-1 mouse responded to lower doses of PFOA, demonstrating 
effects on mammary development at 0.01 and 0.1 mg/kg, along with the higher doses. This 
is likely a reflection of the higher and longer circulating PFOA levels within the blood of the 
CD-1 mice. Although an increase in relative liver weight was evident in CD-1 mice and not 
the C57Bl/6 at 1.0 mg/kg PFOA exposure, we are unclear whether this observation was 
biologically relevant without having measurements from earlier time-points. From these 
data, we suggest that it is the peak serum PFOA concentration that regulates these effects 
(may have occurred between birth and within the first two weeks of life), rather than the 
serum PFOA level at the time of evaluation. This is further supported by earlier findings 
from Macon et al. [15] in which serum collected from a full gestation 1.0 mg/kg PFOA 
revealed that peak concentrations occurred at PND 14, rather than PND 7. To date, serum 
levels between PND 0 and PND 6 have yet to be reported for a full gestation study. In one 
study, where PFOA was administered once during late gestation (GD 17), pup serum 
concentrations peaked at PND 1 for all concentrations [5]. Therefore, the observed effects 
are likely a result of the in utero exposure, followed by exacerbation of effect from the 
exposure during lactation.
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In these studies, PFOA induced abnormal mammary gland development in both strains. This 
suggests that either the other pubertal end points measured have a much different dose 
response threshold or that the hypothalamic ovarian axes that govern the various processes 
differ in their response to PFOA. Full gestation (GD1-17) PFOA exposure studies have 
previously reported delayed mammary development at concentrations ≤ 3.0 mg/kg in the 
CD-1 mouse [15]. Our current findings fully support and extend those previous observations 
with reduced developmental scores at the lowest dose of 0.3 mg/kg, and with an n that is 3-4 
times that in the previous experiments. Previous changes were evident beginning on PND 7 
and persisted until the last collection on PND 84. We confirm here the persistent mammary 
effects at lower doses and also determined through trend analysis that the severity of the 
effects increased with higher doses in both strains (p <0.001). Macon and colleagues [15]] 
also observed reduced mammary gland scores at PND 21 following a late gestation exposure 
(GD10-17) to PFOA in all concentrations including the 0.01 mg/kg dose. While they noted 
reduced mammary developmental scores following PFOA exposure, longitudinal growth 
measurements were only changed in the 1.0 mg/kg group and the number of TEBs were 
significantly reduced in the 0.1 and 1.0 mg/kg groups. All other quantitative measurements, 
however, were similar to age matched controls. Studies comparing the effects of 
peripubertal PFOA exposure in C57Bl/6 and Balb/c have also shown differences by strain in 
mammary gland development [24, 37]. Although they found no significant effects at 1.0 
mg/kg in either strain compared to control for ductal length, number of TEBs or stimulated 
terminal ducts, C57Bl/6 animals had an increased number of TEBs compared to the Balb/c 
at PND 56. Many of the glands from our C57Bl/6 highest dose group (1.0 mg/kg) also 
exhibited poor branching and differentiation; TEBs were very apparent at PND 61, in 
addition to the substantial number of long ducts with little to no branching. Zhao et al. [37] 
also evaluated serum PFOA in C57Bl/6 and Balb/c pups, and as concentrations increased, 
C57Bl/6 mice were shown to have much lower serum PFOA levels compared to Balb/c 
females (≥5 mg/kg). While we are aware of the fact that concentration plays a major role in 
the depth of effects seen, our data further supports that the excretion rate for PFOA varies 
amongst mouse strain, and plays a significant role in whether or not PFOA affects the 
mammary gland at the lowest doses tested. The fact that we saw adverse mammary changes 
in the CD-1 mice at 0.01 and 0.1 mg/kg suggests that this strain is the most sensitive to 
prenatal PFOA exposures for mammary gland developmental delays.
Puberty demarks a pivotal window of susceptibility for environmental exposures and the 
development of endocrine regulated tissues in both humans and rodents. During this period 
of development, upstream pulsatile increases from gonadotropin releasing hormone trigger 
sex hormones, such as estrogen and progesterone, to circulate at higher concentrations. In 
turn, other downstream cues are prompted that result in the occurrence of VO (rodents) or 
first menarche (humans), sexual maturation and rapid mammary gland development. Early 
exposure to EDCs, however, can alter the timing at which these processes occur or alter the 
morphological development altogether resulting in the increased risk of development of 
adulthood diseases, such as breast cancer [21, 22]. Since the onset of puberty is highly 
influenced by sex hormones, we were also interested in measuring circulating estradiol and 
progesterone to determine whether PFOA contributed to altered levels. Progesterone is 
involved in developmental branching [15, 16, 20] and estradiol has both paracrine and 
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endocrine roles in mammary development [15, 16, 20]. We collected all post-pubertal 
animals on the same stage of the estrous cycle (first day of estrus) to minimize variability 
and found no difference in serum estradiol or progesterone in either strain in response to 
PFOA exposure. These findings are both supported and contrasted by the work of Zhao et 
al. [20]. C57Bl/6 mice exposed to 5 mg/kg during adolescence/puberty had no change in 
serum estradiol, yet were reported to have increased levels of progesterone. In a follow up 
study using PFOA doses of 2.5 mg/kg in Balb/c or 7.5 mg/kg in C57Bl/6 the same group of 
researchers were unable to see significant changes in progesterone due to an inadequate 
number of controls in each stage of the estrous cycle; however, they reported a significant 
decrease in ovarian protein levels of StAR, CYP11A1, HSD3β1, HSD17β1, aromatase and 
PPARα, which are all involved in the biosynthesis pathway. Taken together, it appears that 
circulating levels of hormones have little, if any, effect on PFOA-induced decreases in 
mammary branching density. Thus, while other endocrine disruptors have been shown to 
alter estradiol and progesterone levels at much lower doses, we postulate that PFOA may 
alter mammary branching density through other endocrine related mechanisms that are 
specific to the mammary gland.
Evaluation of vaginal cytology is also a valid tool to identify the effects of toxicants, toxins 
or xenobiotics on the hypothalamic-pituitary-ovarian axis in rodents. In mice, VO is thought 
to denote the onset of puberty and is heavily influenced by increases in serum estradiol; 
however, it doesn’t necessarily reflect the onset of sexual maturity. In the untreated CD-1 
mouse VO typically occurs around PND 23, although normal timing to this event can vary 
in other mouse strains. Neither strain in our study exhibited changes in timing of either VO 
or first estrus following prenatal exposure to PFOA. Body weights were unchanged at the 
time of these events, as well (Table 4). Lau et al. [13] have shown a 3 day delay for VO and 
first estrus at 10 mg/kg following prenatal exposure, and consistent with our findings, the 
1.0 mg/kg group showed no effect. Serum levels were not reported in their study but it was 
implied that increased PFOA serum levels in rodents result in greater pubertal delays. 
Although no differences were observed between treated and control animals, there were 
marked differences between the timing of VO and first estrus in CD-1 controls compared to 
C57Bl/6 controls. This observation has been previously noted [29]. Inbred strain 
comparisons at puberty showed that C3H and DBA animals began VO at approximately 
PND 22-24, whereas C57Bl/6 mice were around PND 27 [29]. C57Bl/6 mice were also the 
last to exhibit cornification in that 3-strain comparison. Our data supports these findings and 
reinforces the idea that even in non-treated animals there appears to be differences in genetic 
profiles between strains that govern the timing of these occurrences. This innate difference 
may also influence windows of sensitivity to chemicals. Variability within the outbred CD-1 
strain was also apparent within our vaginal cytology data and thus the reason for 
representing it in two separate blocks. The different seasons during which these blocks were 
tested could have contributed to these differences, as it has been noted that VO tends to 
occur earlier in rodents born during the summer months compared to those born during 
winter [38]. Our animals in block 1 were born in mid-summer whereas block 2 females were 
born during early winter. Body weights at VO in both blocks were similar indicating that our 
second block required additional time to achieve the body weight necessary to begin these 
events.
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Serum PFOA levels were measured in our studies to determine the internal doses required 
for pubertal changes, such as mammary gland development, and also confirmed our lab’s 
previous findings that internal exposures were within the range of serum PFOA levels 
reported in humans living in contaminated areas of the U.S. Children in the Ohio River 
Valley have been reported to have geometric mean (GM) serum PFOA levels as high as 600 
ng/ml [2] and more recently, reports demonstrated levels of PFOA in children aged 12-19 
even within the general population (GM: 1.81 ng/ml) that are comparable to those found in 
adults aged ≥20 (GM 2.12) ([39]). Most noteworthy from these findings are the fact that our 
PND 21 serum concentrations from the 0.01 mg/kg treated groups in both strains fell within 
the serum range reported in male and female participants aged <12 years old from the C8 
Science panel (GM 34.8 ng/ml) [3]. PFOA levels were elevated in a dose dependent manner 
and were within the same range at PND 21 in both strains, and were detectable in the three 
highest treatment groups on the final collection date in each strain.
Interesting correlations between potential rodent and adolescent health impact may be 
realized if the half-life of PFOA following exposure during gestation is compared. With a 
half-life of about 3 years in humans, by the time prenatal exposure had gone through three 
half-lives, a child would be around 9 or 10 years old (average age for Tanner Stage II; [40]). 
Similarly, in the prenatally exposed mouse pup with a PFOA half-life of 6-7 days (as 
calculated from our data), three half-lives would equate to PND 18-21 days old, which is 
also the time that the mammary tissue begins to develop. While there haven’t been any 
reports that have directly linked PFOA exposure to breast developmental timing in girls, 
new evidence suggests that there may be a correlation. Higher serum PFOA levels were 
associated with the length of time that 6-8 year old girls had been breastfed [41] and their 
source of water and serum PFOA concentrations were highly correlated. In another study 
[42], breastfed girl’s experienced delayed onset of breast development in comparison to 
formula fed girls and was even more exacerbated by the length of time that they were 
breastfed.
Girls living in the Ohio River Valley area reported increased delays (self-reported) to 
menarche within the measured concentration ranges that were observed in our 0.01 and 0.1 
mg/kg group. This may indicate a lack of concordance between rodents and humans for 
other pubertal indicator endpoints following PFOA exposure. It has been well documented 
that the mode of action for these pubertal endpoints [43] are fairly different between rodents 
and girls and that VO and time to first estrus in rodents may not be translatable indicators for 
puberty timing in girls.
While most of organogenesis occurs during embryonic development, the mammary gland 
undergoes most of its growth during puberty. Still, exposure to excessive amounts of 
hormones or EDCs too early in life can have a permanent effect on the developing gland. 
Because mammary alterations were documented following early low dose PFOA exposures 
in our study and by others [23], without altering other pubertal endpoints or liver: body 
weight ratios, implies that the mammary gland may be the most sensitive tissue to the 
prenatal effects of PFOA. This can also be said for other chemicals in which the mammary 
gland has been studied. Early exposure to human relevant levels of endocrine disruptors in 
rodents has led to both accelerated (Bisphenol A) and delayed mammary gland growth 
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(TCDD and atrazine) that have presented in the form of an extended presence of TEBs [44], 
increased stromal and epithelial tissue and sensitization to estradiol [45, 46, 47]. Some of 
those chemicals, as well as PFOA [23, 48], have adversely affected the lactational capacity 
of rodents to nourish their litters. Dams [48] and their F1 offspring [23] demonstrate 
abnormal lactating gland morphology, decreased pup weight, and/or altered milk protein 
gene expression following exposure to PFOA during pregnancy. Studies using slightly 
higher exposures of PFOA [49] have also shown that the developmental effects of prenatal 
exposure had long-lasting effects; increased stromal hyperplasia and disorganized, scant 
mammary epithelium were reported in 18 month old PFOA-exposed mice.
The hypothesized mode of action for some of these chemicals involves either direct or 
indirect alterations to key receptors, such as ERα, or their corresponding signaling 
pathways. At least within the mammary gland PFOA has been shown to not directly bind to 
the ERα, nor cause a stimulatory effect in ovariectomized animals [20]. PPARα knock-out 
mice exhibit mammary effects following a peripubertal exposure indicating that PPARα 
may not play a predominate role in the mammary gland changes observed after PFOA 
exposure as those seen in rodent livers [20]. Work by Macon and colleagues (in press) 
suggest that post transcriptional modifications may play a role in the observed mammary 
changes [50]. Pparα and γ expression were decreased in microarray validation studies, 
however, only Pparγ protein levels were increased. Additionally, Pparγ molecular weight 
shifts were also found in Westerns, leading the authors to propose phosphorylating 
modifications. The stroma may play an important role, as lipid metabolism genes were also 
found to be altered. Therefore, we conclude that during early PFOA exposures post- 
transcriptional modifications in the gland itself may be responsible for the altered epithelium 
and microenvironment. Also, since PFOA was still present in the serum 5 weeks following 
weaning, as a result of a lactational exposure, the effects may have been compounded and 
the peripubertal mechanism suggested by Zhao et al. [20] may have also taken effect. 
Regardless of the mechanism behind the outcome, each of these chemicals, including PFOA, 
has the potential to significantly alter the glands normal development, thereby increasing the 
gland’s risk to further environmental insults.
The few studies that have tried to correlate breast cancer risks to perfluorinated chemicals 
(PFCs) found that in a Greenland Inuit cohort the PFC levels were linear to the cancer risks 
[51], while a Danish cohort reported weak significance [52]. Whether PFOA directly causes 
cancer still requires additional evaluation, however, the delayed phenotype that it creates in 
the rodent ultimately leaves the gland more susceptible to other harmful exposures. Because 
of the potential for increased lifetime susceptibility to disease or dysfunction, pubertal 
assessments of chemical effect performed in rodent models should include an evaluation of 
the mammary gland. This suggestion has recently been echoed by the scientific community 
[53, 54, 55]. It will also be necessary to evaluate for changes in breast development based on 
early life or cord blood PFOA levels in future epidemiological studies.
Although PFOA production and use in the USA is scheduled to be phased out by 2015 [55], 
its lasting effects may continue to be seen well after this time due to its persistence within 
the environment and long half-life in humans. Because PFOA exposure occurs throughout 
the lifetime in humans, it may be necessary to continue monitoring heavily exposed 
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populations to determine if later life diseases arise. These studies confirm that the mammary 
gland is highly sensitive to low dose prenatal PFOA exposure. Our findings suggest that 
measures should be put in place to limit PFOA exposures in sensitive populations, especially 
in pregnant women and prepubescent females. Decreased exposure could potentially 
minimize early life effects, as well as those that may manifest throughout life, to reduce 
mammary gland susceptibility for later life disease and dysfunction.
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• Given an identical oral exposure, C57Bl/6 offspring achieve lower serum PFOA 
than CD-1
• In utero exposure to PFOA stunts the developing mammary gland of CD-1 and 
C57Bl/6 mice
• Mouse pups demonstrate a potential for a shorter PFOA half-life than adult mice
• Early PFOA exposure alters the mammary gland without changing other 
pubertal endpoints
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Effects of PFOA treatment on serum hormone levels A) estradiol B) progesterone levels. All 
animals were sacrificed during estrus, with the exception of PND 21 when vaginal opening 
had not occurred. CD-1 litter/treatment group n=12-15 (PND 21), n=9-10 (PND 35) and 
n=8-10 (PND 56). C57Bl/6 litter n= 3-4 (PND 21) and n=3-9 (PND 61). Data presented as 
the mean ± SEM.
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Mammary whole mount assessment of early and late pubertal glands in CD-1 offspring. 
Representative image of control A) PND 21, F) PND 35, and K) PND 56; 0.01 mg/kg B) 
PND 21, G) PND 35 and L) PND 56, 0.1 mg/kg C) PND 21, H)PND 35 and M)PND 56; 0.3 
mg/kg D) PND 21, I) PND 35 and N) PND 56 and 1.0 mg/kg E) PND 21, J) PND 35 and 
O)PND 56. CD-1 n= 4-11 litters/treatment group. Significant inverse trends were noted 
between developmental scores and PFOA dose, indicating higher PFOA exposure was 
related to lower (more severe) developmental scores (p<0.05).
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Mammary whole mount assessment of early and late pubertal glands in C57Bl/6 offspring. 
Representative image of control A) PND 21 and F) PND 61, 0.01 mg/kg B)PND 21 and G) 
PND 61, 0.1 mg/kg C) PND 21 and H)PND 61, 0.3 mg/kg D) PND 21 I) PND 61 and 1.0 
mg/kg E) PND 21 and J) PND 61. C57Bl/6 n=2-10 litters/treatment group. Significant 
inverse trends were noted between developmental scores and PFOA dose, indicating higher 
PFOA exposure was related to lower (more severe) developmental scores (p<0.05).
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Table 1
PFOA Serum Concentrations in CD-1 and C57Bl/6 Mice
Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n)
CD-1
PND 21 <LOQ (6) 74.8 ± 16.9 (10) 457.3± 91.0 (9) 904.8 ± 131.5 (10)* 3119.0 ± 396.4 (5)**
PND 35 <LOQ (11) 14.3 ± 2.3 (12) 61.7 ± 6.5 (9) 200.9 ± 32.2 (11)* 889.8 ± 117.5 (11)**
PND 56 < LOQ (5) < LOQ (5) 15.0 ± 5.0 (4) 46.2 ± 7.5 (6) 200.2 ± 21.1 (7)**
C57Bl/6
PND 21 <LOQ (2) 26.1 ± 19.0 (2) 247.1 ± 11.4 (2) 891.3 ± 528.7 (3) 2141.67 ± 666.8 (2)
PND 61 <LOQ (6) <LOQ (2) 27.7 ± 10.4 (3)* 9.3± 2.2 (5) 22.0 ± 7.6 (5)
Data presented as the mean ± SEM. Significance observed in comparison to control;
*
p≤0.05.
The LOQ (limit of quantitation) for C57Bl/6 animals was <10 ng/ml. CD-1 LOQ: Control 5 ng/ml, 0.01mg/kg=10 ng/ml, 0.1, 0.3 and 1.0 mg/
kg=100 ng/ml. All controls at PND 21 and 61 and 0.01, 0.1 and 0.3 mg/kg at PND 61 were <LOQ.
(n) = # of animals per dose group; CD-1 n= 4-12; C57Bl/6 n= 2-6
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Table 2
Body and Liver Weights of Female CD-1 Mice
Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n)
Body Weight (g)
PND 21 11.9 ± 0.2 (20) 12.1 ± 0.2 (22) 12.5 ± 0.3 (22) 11.6 ± 0.3 (22) 10.9 ± 0.2 (21)
PND 35 23.1 ± 0.3 (17) 22.9 ± 0.5 (16) 23.0 ± 0.4 (14) 22.2 ± 0.3 (17) 21.8 ± 0.4 (16)
PND 56 26.6 ± 0.8 (9) 27.7 ± 0.7 (14) 27.6 ± 0.2 (8) 25.69 ± 0.83 (4) 28.5 ± 0.7 (9)
Net Body Weight (g)
PND 21 11.3 ± 0.2 (19) 11.5 ± 0.2 (22) 11.9 ± 0.3 (22) 11.1 ± 0.3 (22) 10.3 ± 0.2 (21)*
PND 35 22.0 ± 0.3 (17) 21.7 ± 0.4 (16) 21.9 ± 0.4 (14) 21.1 ± 0.3 (17) 20.7 ± 0.3 (16)*
PND 56 25.2 ± 0.8 (9) 26.3 ± 0.7 (13) 26.3 ± 0.2 (8) 25.6 ± 0.5 (10) 27.1 ± 0.6 (9)
Absolute Liver Weight (g)
PND 21 0.60 ± 0.02 (19) 0.62 ± 0.02 (22) 0.61 ± 0.02 (22) 0.59 ± 0.02 (22) 0.62 ± 0.02 (21)
PND 35 1.16 ± 0.03 (17) 1.14 ± 0.04 (16) 1.13 ± 0.04 (14) 1.13 ± 0.02 (17) 1.13 ± 0.04 (16)
PND 56 1.36 ± 0.05 (9) 1.35 ± 0.04 (13) 1.29 ± 0.03 (8) 1.22 ± 0.02 (10) 1.36 ± 0.07 (9)
Relative Liver
PND 21 0.051 ± 0.002 (19) 0.051 ± 0.001 (22) 0.049 ± 0.001 (22) 0.051 ± 0.001 (22) 0.057 ± 0.001 (21)*
PND 35 0.050 ± 0.001 (17) 0.050 ± 0.002 (16) 0.049 ± 0.002 (14) 0.051 ± 0.001 (17) 0.051 ± 0.001 (16)
PND 56 0.052 ± 0.002 (9) 0.048 ± 0.003 (13) 0.047 ± 0.001 (8) 0.046 ± 0.001 (10)* 0.048 ± 0.001 (9)
Data are represented as mean ± SEM. Significance observed in comparison to control;
*
p≤0.05
Net Body Weight= Body weight (g) – Liver Weight (g); Relative Liver weight = Body weight (g)/Liver weight (g)
(n) = # of animals per dose group; n= 8-22













Tucker et al. Page 25
Table 3
Body and Liver Weights of Female C57Bl/6 Mice
Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n)
Body Weight (g)
PND 21 8.4 ± 0.4 (6) 8.6 ± 0.1 (4) 9.5 ± 0.9 (2) 8.2 ± 0.7 (5) 7.5 ± 0.3 (5)
PND 61 19.1 ± 0.3 (9) 19.8 ± 0.3 (5) 20.1 ± 0.5 (3) 20.1 ± 0.4 (9) 19.9 ± 0.5 (8)
Net Body Weight (g)
PND 21 8.0 ± 0.4 (6) 8.3 ± 0.03 (4) 9.1 ± 0.9 (2) 7.9 ± 0.6 (5) 7.1 ± 0.3 (5)
PND 61 18.2 ± 0.2 (9) 18.8 ± 0.3 (5) 19.2 ± 0.5 (3) 19.2 ± 0.3 (9) 19.0 ± 0.4 (8)
Absolute Liver Weight (g)
PND 21 0.37 ± 0.03 (6) 0.43 ± 0.04 (4) 0.45 ± 0.03 (3) 0.38 ± 0.03 (6) 0.39 ± 0.01 (5)
PND 61 0.93 ± 0.02 (9) 0.97 ± 0.03 (5) 0.90 ± 0.05 (3) 0.95 ± 0.05 (9) 0.89 ± 0.03 (8)
Relative Liver
PND 21 0.044 ± 0.002 (6) 0.049 ± 0.004 (4) 0.048 ± 0.001 (2) 0.045 ± 0.001 (5) 0.052 ± 0.001 (5)
PND 61 0.048 ± 0.001 (9) 0.049 ± 0.001 (5) 0.045 ± 0.002 (3) 0.047 ± 0.002 (9) 0.045 ± 0.002 (8)
Data are represented as mean ± SEM
Net Body Weight= Body weight (g) – Liver Weight (g); Relative Liver weight = Body weight (g)/Liver weight (g)
(n) = # of animals per dose group; N= 2-9
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Table 4
Assessment of Female Pubertal Events Following Prenatal PFOA Exposures in CD-1 and C57Bl/6 Mice
Control 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n)
CD-1 (Block 1)
Vaginal Opening 22.8 ± 0.7 (8) 24.1 ± 0.7 (11) 23.8 ± 0.9 (7) 25.7 ± 0.6 (7) 23.9 ± 0.7 (10)
Vaginal Opening BW 13.8 ± 0.5 (8) 14.2 ± 0.6 (11) 15.6 ± 0.9 (7) 16.6 ± 1.8 (7) 14.6 ± 0.8 (10)
First Estrus 25.1 ± 0.6 (8) 26.7 ± 0.7 (11) 26.1 ± 0.9 (7) 28.2 ± 0.6 (7) 26.3 ± 0.6 (10)
CD-1 (Block 2)
Vaginal Opening 28.2 ± 1.4 (5) 27.5 ± 1.2 (6) 28.8 ± 0.4 (5) 28.1 ± 1.4 (5) 26.6 ± 0.9 (4)
Vaginal Opening BW 18.5 ± 1.2 (5) 18.5 ± 1.5 (6) 19.5 ± 0.4 (5) 18.5 ± 0.9 (5) 17.5 ± 1.0 (4)
First Estrus 28.8 ± 1.2 (5) 29.8 ± 1.2 (6) 28.9 ± 0.4 (5) 29.2 ± 1.4 (5) 29.1 ± 0.4 (4)
C57Bl/6
Vaginal Opening 31.7 ± 0.8 (7) 31.2 ± 0.4 (3) 29.9 ± 0.3 (3) 31.3 ± 0.7 (5) 31.6 ± 0.6 (5)
Vaginal Opening BW 14.8 ± 0.2 (7) 14.9 ± 0.3 (3) 14.8 ± 0.7 (3) 15.4 ± 0.2 (5) 14.5 ± 0.4 (5)
First Estrus 33.6 ± 0.9 (7) 32.9 ± 0.1 (3) 31.9 ± 1.0 (3) 31.7 ± 0.7 (5) 32.4 ± 0.8 (5)
Data are represented as mean ± SEM. All animals evaluated within each block were assessed as close as possible to the same time of day to 
minimalize variability.
(n) = # of animals per dose group; CD-1 n= 4-11; C57Bl/6 n=3-7
Units for these measures are as follows: Vaginal opening and first estrus are postnatal age in days and body weight (BW) is reported in grams.
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Table 5
Mammary Gland Developmental Scores
Control (n) 0.01 mg/kg (n) 0.1 mg/kg (n) 0.3 mg/kg (n) 1.0 mg/kg (n)
CD-1
PND 21 2.9 ± 0.1 (19) 2.4 ± 0.1 (22) 2.3 ± 0.1 (22)** 2.0 ± 0.1 (21)*** 1.7 ± 0.1 (21)****
PND 35 3.1 ± 0.1 (16) 2.3 ± 0.2 (17)** 2.2 ± 0.2 (14)** 2.3 ± 0.1 (16)** 1.9 ± 0.2 (14)****
PND 56 3.3 ± 0.1 (9) 2.3 ± 0.2 (13)** 2.5 ± 0.2 (8)* 2.2 ± 0.1 (10)** 1.9 ± 0.2 (9)****
C57Bl/6
PND 21 2.9 ± 0.2 (7) 2.5 ± 0.4 (5) 2.1 ± 0.7 (2) 1.8 ± 0.3 (6)* 1.8 ± 0.2 (5)*
PND 61 2.8 ± 0.2 (10) 2.2 ± 0.2 (5) 2.6 ± 0.1 (3) 2.1 ± 0.1 (10)* 1.7 ± 0.1 (8)***
Data are represented as mean ± SEM. Mammary glands scored between 1 (poor development) and 4(best development). Individual pup scores were 
averaged and are represented by the mean values for each treatment group.
(n) = # of animals per dose group; CD-1 n= 8-19 and C57Bl/6 n=2-10.
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